# Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer

> **NCT00889343** · PHASE2 · TERMINATED · sponsor: **AIO-Studien-gGmbH** · enrollment: 101 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** Sorafenib
- **DRUG:** Placebo
- **DRUG:** Oxaliplatin or Irinotecan
- **DRUG:** Leucovorin
- **DRUG:** 5-Fluorouracil

## Key facts

- **NCT ID:** NCT00889343
- **Lead sponsor:** AIO-Studien-gGmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-03
- **Primary completion:** 2011-11
- **Final completion:** 2012-12
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2013-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00889343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00889343, "Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00889343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*